Clinical trials: Cytoreductive Surgery
Peritoneal Carcinomatosis
Cytoreduction Followed by Normothermic Versus Hyperthermic Intraperitoneal Intraoperative Chemoperfusion (HIPEC): a Study in Peritoneal Carcinomatosis
Peritoneal carcinomatosis from appendix or colon (large bowel) cancer is treated in suitable patients with surgery followed by instillation of heated chemotherapy inside the abdominal cavity.
- Trial name
- NCT01575730
- Testing
- Hyperthermic intraoperative Peritoneal Chemoperfusion
- Where
- Belgium
- Volunteers
- 45 people
- Sponsor
- University Hospital, Ghent
Cytoreductive Surgery, Hyperthermic Intraperitoneal Chemotherapy
Anesthesia Management in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
A combined approach of cytoreductive surgery (SRC) and hyperthermic intraperitoneal chemotherapy (HIPEC) represents a potential treatment option for patients diagnosed with primary or secondary gastrointestinal or gynaecological…
- Conditions
- Cytoreductive Surgery, Hyperthermic Intraperitoneal Chemotherapy, Anesthesia
- Trial name
- NCT06398678
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Sanliurfa Mehmet Akif Inan Education and Research Hospital
Long Term, Quality of Life
Long-Term Quality Of Life And Symptom Assessment Among Recurrence-Free Patients Who Underwent Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
To evaluate long-term quality of life (QoL) and participant reported symptom burden in disease-free survivors who have undergone cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) at MD Anderson…
- Conditions
- Long Term, Quality of Life, Recurrence Free, Cytoreductive Surgery
- Trial name
- NCT07871760
- Testing
- Questionnaire and Physical Exam
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- M.D. Anderson Cancer Center
Epithelial Ovarian Cancer
Microscopic Peritoneal Metastases After Complete Macroscopic Cytoreductive Surgery for Epithelial Ovarian Cancer
The objective of the cytoreductive surgery carried out for the management of ovarian cancers is to obtain a complete macroscopic cytoreduction. This means that all visible peritoneal metastases must be resected.
- Trial name
- MicroPCI (NCT03754569)
- Testing
- Peritoneal biopsies after complete macroscopic cytoreduction
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Peritoneal Metastases, Peritoneal Carcinomatosis
Changes in Coagulation in Colorectal Cancer Patients Undergoing Surgical Treatment
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) has prolonged the survival substantially for selected patients with peritoneal metastases from colorectal cancer.Bleeding and thromboembolic disease…
- Conditions
- Peritoneal Metastases, Peritoneal Carcinomatosis, Colorectal Neoplasms Malignant, Intestinal Neoplasms
- Trial name
- CONTEST (NCT04744688)
- Where
- 2 sites in Denmark
- Volunteers
- 90 people
- Sponsor
- University of Aarhus
Epithelial Ovarian Cancer, Fallopian Tube Neoplasms
SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery
An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- SUROVA (NCT06223763)
- Testing
- Cytoreductive surgery, Neoadjuvant chemotherapy, Adjuvant chemotherapy
- Where
- Spain
- Volunteers
- 5,000 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Peritoneal Carcinomatosis
Preoperative Inflammatory Markers Predict Postoperative Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Colorectal Carcinomatosis
A retrospective study of a single-center prospective database of patients who underwent curative CRS-HIPEC for peritoneal carcinomatosis (PC) of colo-rectal cancer (CRC), between September 2012 and July 2023 at Reims…
- Trial name
- NCT06318793
- Where
- France
- Volunteers
- 166 people
- Sponsor
- CHU de Reims
Cancer
Electroacupuncture in Symptom Management After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
The investigators are conducting this research study is to evaluate the feasibility (recruitment, compliance, safety, and acceptance) of using electroacupuncture (EA) to manage complex symptoms such as pain, nausea/vomiting…
- Trial name
- NCT06340906
- Testing
- Electroacupuncture
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of California, Irvine
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Telehealth Intervention for Improving Distress and Financial Toxicity in the Caregivers
This clinical trial assesses whether resource identification for primary caregivers can affect financial stress, quality of life, depression, and the general belief in the ability to cope with daily life.
- Trial name
- NCT06709404
- Testing
- Telemedicine, Survey administration, Electronic health record review
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Wake Forest University Health Sciences
Ovary Cancer
An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery
This study looks to enroll subjects with ovarian cancer who will be having standard of care surgery to remove ovarian cancer tumors.
- Trial name
- NCT03011320
- Testing
- EC1456, 99mTc-Etarfolatide
- Where
- 2 sites in United States, Canada
- Volunteers
- 3 people
- Sponsor
- Endocyte
Relapsed/Refractory, B-cell Acute Lymphocytic Leukemia
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
To learn about the safety of giving the drug brexucabtagene autoleucel to participants with relapsed/refractory B-cell ALL after treatment with inotuzumab ozogamicin, blinatumomab, and either hyper-CVAD or mini-hyper-CVD.
- Trial name
- NCT06287229
- Testing
- Blinatumomab, Inotuzumab Ozogamicin, Hyper-CVAD
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer, Fallopian Tubes Cancer
Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The purpose of this study is to see if the investigators can improve the treatment of this type of cancer. They want to find out what effects, good and/or bad, giving heated chemotherapy into the belly, known as hyperthermic…
- Conditions
- Ovarian Cancer, Fallopian Tubes Cancer, Peritoneal Cancer
- Trial name
- NCT01767675
- Testing
- Secondary Cytoreductive Surgery, Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC), platinum-based systemic chemotherapy postoperatively
- Where
- 11 sites in United States
- Volunteers
- 99 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
D010051, Ovarian Cancer
Validation of ESGO Quality Indicators in Advanced Ovarian Cancer Surgery
This study, organized by the European Society of Gynaecological Oncology (ESGO), evaluates the clinical impact of adherence to ten ESGO-established quality indicators (QIs) in advanced ovarian cancer surgery.
- Conditions
- D010051, Ovarian Cancer, Advanced-stage Ovarian Cancer, FIGO Stages III and IV
- Trial name
- retroESGO ov1 (NCT07567573)
- Testing
- Preoperative Evaluations, Cytoreductive Surgery, Perioperative Management
- Where
- Belgium
- Volunteers
- 11,383 people
- Sponsor
- European Society of Gynaecological Oncology
Renal Cell Cancer, Kidney Neoplasm
Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.
This is Phase IV, randomized, multi arm, multicenter, low interventional clinical trial, aiming to evaluate if treatment of primary tumor in mRCC patients with initial benefit to anti-PD1- based therapy (SOC) can improve the…
- Conditions
- Renal Cell Cancer, Kidney Neoplasm, Immunotherapy, Kidney Cancer
- Trial name
- ITALIC-RCC (NCT06903312)
- Testing
- Deferred Cytoreductive Nephrectomy + medical treatment, Radiotherapy + medical treatment, Medical therapy
- Where
- Italy
- Volunteers
- 409 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Prostate Adenocarcinoma
Neoadjuvant Embolization and Cytoreduction in Prostate Cancer
The goal of this clinical trial is to find out whether prostate artery embolization (PAE) can help prevent or lessen urinary side effects caused by radiotherapy (RT) in people with prostate cancer, especially those who have…
- Trial name
- NCT07251829
- Testing
- Prostatic Artery Embolization
- Volunteers
- 35 people
- Sponsor
- Srinivas Raman
Peritoneal Carcinosis (PC)
Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan
This is an open, non-randomized, phase I-II, pilot study, which evaluates the combination of optimum cytoreductive surgery and hyperthermic intraoperative peritoneal chemotherapy (HIPEC) with mitomycin C (MMC) and irinotecan.
- Trial name
- NCT01226550
- Testing
- cytoreductive surgery and HIPEC
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Hospices Civils de Lyon
Colorectal Cancer, Ovarian Cancer
An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Peritoneal carcinomatosis is a common event in the natural history of colorectal and other digestive tract cancers. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) provides a promising…
- Conditions
- Colorectal Cancer, Ovarian Cancer, Peritoneal Disease
- Trial name
- NCT02754115
- Testing
- Hyperthermic intraperitoneal chemotherapy
- Where
- India
- Volunteers
- 400 people
- Sponsor
- Tata Memorial Centre
Peritoneal Metastases From Colorectal Cancer
Patient-tailored Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Metastases (OrganoHIPEC)
The objective of this clinical trial is to demonstrate that cytoreductive surgery and patient-tailored hyperthermic intra-peritoneal chemotherapy (HIPEC) will increase efficacy in controlling peritoneal disease.
- Trial name
- OrganoHIPEC (NCT06057298)
- Testing
- Patient-tailored hyperthermic intraperitoneal chemotherapy (HIPEC)
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Gastric Cancer With Peritoneal Metastasis (PCI<12)
A Phase Ib/II Study of Efficacy and Feasibility of Cytoreductive Surgery, Extensive Peritoneal Lavage, Hyperthermicintraperitoneal Chemotherapy and Post-operative Intraperitoneal Chemotherapy Combination in Gastric Cancer With Peritoneal Metastasis
This is an open-label, non-randomized, single-center, phase Ib/II study, evaluating efficacy and feasibility of cytoreductive surgery(CRS), extensive peritoneal lavage, hyperthermic intraperitoneal chemotherapy(HIPEC) and…
- Trial name
- NCT02995850
- Testing
- CRS+HIPEC
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Yonsei University
B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Small Lymphocytic Lymphoma
Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase I trial is studying the side effects and best dose of flavopiridol in treating patients with B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Stage I Chronic Lymphocytic Leukemia
- Trial name
- NCT00377104
- Testing
- alvocidib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)